Repeat COVID-19 vaccinations elicit antibodies that neutralize variants, other viruses
On May 17, 2024, researchers at Washington University School of Medicine in St. Louis announced a study had…
-
-
Novavax and Sanofi announced licensing agreement to co-commercialize COVID-19 vaccine and novel COVID-19-influenza combination vaccines
On May 10, 2024, Novavax announced that it had entered into a co-exclusive licensing agreement with Sanofi. The…
-
COVID vaccines not linked to seizures
On Apr. 30, 2024, a meta-analysis of six randomized controlled trials in JAMA Neurology found no increase in seizures in…
-
Moderna announced contract with Brazil to supply 12.5 million COVID-19 vaccines as part of national vaccination campaign
On Apr. 22, 2024, Moderna announced a contract with the Ministry of Health in Brazil (Ministerio da Saude)…
-
Study suggested staying current with COVID-19 vaccinations helped combat emerging variants
On Apr. 12, 2024, Oregon Health Sciences University (OHSU) announced research that shows using live SARS-CoV-2 virus revealed…
-
WHO launched CoViNet: a global network for coronaviruses
On Mar. 27, 2024, the World Health Organization announced it had launched a network for coronaviruses, CoViNet, to…
-
FDA issued EUA for Pemgarda (pemivibart) for pre-exposure prophylaxis of COVID-19 in certain adults and adolescents
On Mar. 22, 2024, the U.S. Food and Drug Administration (FDA) issued the an emergency use authorization for…
-
Cardiology | COVID-19 | Imaging | Infectious Disease | NIH | Therapeutics
Severe lung infection during COVID-19 caused damage to the heart
On Mar. 20, 2024, a National Institutes of Health-supported study reported that SARS-CoV-2, the virus that causes COVID-19,…
-
CDC projected JN.1 variant of SARS-CoV-2 to account for 39-50% of circulating variants in the U.S.
On Dec. 22, 2023, the U.S. Centers for Disease Control and Prevention (CDC) projected the JN.1 variant of…
-
SARS-CoV-2 rebound with and without use of COVID-19 oral antivirals
On Dec. 22, 2023, the U.S. Centers for Disease Control and Prevention (CDC) announced study results that showed…
-
CCSL and Arcturus Therapeutics’ ARCT-154 Demonstrated Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
On Dec. 21, 2023, CSL and and Arcturus Therapeutics announced the results of a Phase 3 study showing…
-
NIAID scientists found Infectious SARS-CoV-2 in patient blood
On Dec. 13, 2023, National Institute of Allergy and Infectious Diseases (NIAID) scientists announced findings published in the…
-
Novavax’s updated COVID-19 vaccine received Emergency Use Authorization in the Republic of Korea
On Dec. 5, 2023, Novavax announced that Health Canada had granted expanded authorization for Nuvaxovid XBB.1.5 Vaccine (Recombinant…
-
Upsurge of respiratory illnesses reported among children in Northern China
On Nov. 23, 2023, the World Health Organization (WHO) announced that it was monitoring data from Chinese surveillance…
-
CDC expanded testing of international air traveler samples to include flu RSV, and other respiratory viruses
On Nov. 6, 2023, the U.S. Centers for Disease Control and Prevention (CDC) announced that it was conducting…
-
Novavax’s updated COVID-19 vaccine approved in the EU
On Oct. 31, 2023, Novavax announced that the European Commission had granted approval for Nuvaxovid XBB.1.5 dispersion for…
-
FDA authorized updated Novavax COVID-19 vaccine formulated to better protect against currently circulating variant
On Oct. 3, 2023, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) of…
-
SARS-CoV-2 infects coronary arteries, increases plaque inflammation
On Sept. 28, 2023, the National Institute of health announced SARS-CoV-2, the virus that causes COVID-19, can directly…
-
Moderna received U.S. FDA approval for updated COVID-19 vaccine
On Sept. 11, 2023, Moderna announced the U.S. Food and Drug Administration (FDA) had approved the supplemental Biologics…
-
COVID-19 | FDA | Infectious Disease | Vaccine
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
On Aug. 30, 2023, Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP)…
-
CDC reported risk assessment summary for SARS CoV-2 sublineage BA.2.86
On Aug. 23, 2023, the CDC announced it had detected a new SARS-CoV-2 variant labeled BA.2.86. CDC was…
-
COVID-19 vaccination and boosting during pregnancy benefits pregnant women and newborns
On Aug. 11, 2023, a study funded by the National Institute of Allergy and Infectious Diseases (NIAID) reported…
-
BD received 510(k) clearance for COVID-19, influenza A/B, RSV molecular combination test
On Aug. 1, 2023, BD announced that the U.S. Food and Drug Administration (FDA) 510(k) had provided clearance…
-
Report published in Nature detailed transmission of SARS-CoV-2 in free-ranging white-tailed deer in the U.S.
On Jul. 10, 2023, a report published in the journal Nature detailed frequent spillovers of SARS-CoV-2 from humans…
-
University of Illinois Urbana-Champaign team developed all-species coronavirus test
On Jul. 6, 2023, University of Illinois Urbana-Champaign researchers reported they can detect exposure to the SARS-CoV-2 virus…
-
U.S. FDA updated COVID-19 vaccines for use in the U.S. beginning in Fall 2023
On Jun. 16, 2023, the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee…
-
U.S. FDA permitted marketing of first COVID-19 at-home test using traditional premarket review process
On Jun. 6, 2023, the U.S. Food and Drug Administration (FDA) granted granted marketing authorization for the Cue COVID-19…
-
WHO announced simple, easy-to-say labels for SARS-CoV-2 Variants of Interest and Concern
On May 31, 2023, the World Health Organization (WHO) announced it had assigned simple, easy to say and…
-
Novavax’s Nuvaxovid received positive CHMP opinion for full marketing authorization for prevention of COVID in the EU
On May 26, 2023, Novavax announced that Nuvaxovid (NVX-CoV2373) had been recommended for full Marketing Authorization (MA) for…
-
U.S. FDA approved Paxlovid, first oral antiviral for treatment of COVID-19 in adults
On May 25, 2023, the U.S. Food and Drug Administration (FDA) approved the oral antiviral Paxlovid (nirmatrelvir tablets…
